Fundraising Fox

Megan Blewett

Investor

Principal at Scion Life Sciences

San Francisco Bay Area

Writes $10K – $100K checks Β· typically $50K

30 Under 30 2019 Β· Healthcare

About

Megan Blewett joined Scion Life Sciences as a Principal on the investment team in 2025. She was previously an investor at Venrock, where she co-founded Kelonia Therapeutics (acquired by Eli Lilly) and Iris Medicine, later taking operating roles at both companies, including serving as President of Iris Medicine. She earned a PhD as a Hertz Fellow from the Scripps Research Institute and holds an AB/AM in chemistry from Harvard.

Invests in

Biotech

Experience

  1. Scion Life SciencesPrincipalcurrent2025 β€” presentNew York, New York, United States
  2. Hertz FoundationBoard Membercurrent2026 β€” present
  3. Convergent ResearchBoard Membercurrent2022 β€” present
  4. Iris MedicineCo-Founder and President2024 β€” 2025
  5. Iris MedicineCo-Founder and VP Corporate Development2022 β€” 2024
  6. Kelonia TherapeuticsCo-Founder and Director of Business Development2019 β€” 2021
  7. VenrockLife sciences investor2017 β€” 2020Palo Alto, CA

Education

  1. Harvard UniversityAB/AM, Chemistry2007 β€” 2011
  2. Scripps ResearchDoctor of Philosophy (Ph.D.), Chemistry2012 β€” 2016

Skills & more

Biochemistry12Mass Spectrometry11Bioinformatics5Molecular Biology10Organic Synthesis10Chemistry10Organic Chemistry8Proteomics5Metabolomics2Immunology7NMR6Biotechnology2

Languages French Β· Mandarin

From Megan's professional profile.

Same school

Shared employers

Investments

Investor

Iris MedicineKelonia Therapeutics

Per the firm's website.

Colleagues at Scion Life Sciences